{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:07:36Z","timestamp":1760144856933},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.3816\/clm.2006.n.038","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:46Z","timestamp":1221095446000},"page":"42-50","source":"Crossref","is-referenced-by-count":4,"title":["Supportive Care in Multiple Myeloma"],"prefix":"10.3816","volume":"7","author":[{"given":"Asher","family":"Chanan-Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kena C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2006.n.038_bib1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib2","series-title":"Multiple Myeloma and Related Plasma Cell Disorders","first-page":"54","article-title":"Multiple Myeloma","author":"Dispenzieri","year":"2004"},{"key":"10.3816\/CLM.2006.n.038_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib4","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc952","article-title":"Molecular mechanisms of novel therapeutic approaches for multiple myeloma","volume":"2","author":"Hideshima","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"16 suppl","key":"10.3816\/CLM.2006.n.038_bib6","first-page":"605s","article-title":"Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM)","volume":"23","author":"Chanan-Khan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib7","doi-asserted-by":"crossref","first-page":"6a","DOI":"10.1182\/blood.V106.11.6.6","article-title":"Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010)","author":"Dimopoulos","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib8","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or highdose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib9","doi-asserted-by":"crossref","first-page":"665a","DOI":"10.1182\/blood.V104.11.2421.2421","article-title":"A phase II study of velcade (V), doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM)","volume":"104","author":"Chanan-Khan","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib10","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (REV\/DEX) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib11","first-page":"15","article-title":"Pathophysiology of bone cancer pain","volume":"3","author":"Sabino","year":"2005","journal-title":"J Support Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"7","author":"Weinfurt","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib13","first-page":"15","article-title":"Cancer-related pain and its pharmacologic management in the patient with bone metastasis","volume":"4","author":"Slatkin","year":"2006","journal-title":"J Support Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00520-004-0720-4","article-title":"The role of tramadol in cancer pain treatment\u2013a review","volume":"13","author":"Leppert","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.3816\/CLM.2006.n.038_bib15","first-page":"1499","article-title":"The pharmacologic management of cancer pain","volume":"18","author":"Cherny","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CLM.2006.n.038_bib16","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.2004.08.141","article-title":"Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group","volume":"22","author":"Caraceni","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/0470869127.ch16","article-title":"A mechanism-based understanding of bone cancer pain","volume":"261","author":"Mantyh","year":"2004","journal-title":"Novartis Found Symp"},{"key":"10.3816\/CLM.2006.n.038_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1191\/0269216304pm887ra","article-title":"The pathophysiology of cancer-induced bone pain: current understanding","volume":"18","author":"Urch","year":"2004","journal-title":"Palliat Med"},{"key":"10.3816\/CLM.2006.n.038_bib19","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib20","series-title":"Cancer pain relief and palliative care: report of a WHO expert panel. WHO Technical Report 804","author":"World Health Organization","year":"1990"},{"key":"10.3816\/CLM.2006.n.038_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/030089160409000106","article-title":"Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma","volume":"90","author":"Masala","year":"2004","journal-title":"Tumori"},{"key":"10.3816\/CLM.2006.n.038_bib22","first-page":"177","article-title":"Percutaneous vertebroplasty in patients with osteolytic metastases or multiple myeloma","volume":"64","author":"Cortet","year":"1997","journal-title":"Rev Rhum Engl Ed"},{"key":"10.3816\/CLM.2006.n.038_bib23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.n.038_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01682343","article-title":"The role of bisphosphonates in the treatment of bone metastases\u2013the U.S. experience","volume":"4","author":"Harvey","year":"1996","journal-title":"Support Care Cancer"},{"key":"10.3816\/CLM.2006.n.038_bib25","first-page":"5","article-title":"Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients\u2013the American experience","volume":"87","author":"Berenson","year":"1996","journal-title":"Br J Clin Pract Suppl"},{"key":"10.3816\/CLM.2006.n.038_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib27","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2006.n.038_bib28","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib29","first-page":"233","article-title":"Anemia in multiple myeloma","volume":"2","author":"Ludwig","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"issue":"suppl 1","key":"10.3816\/CLM.2006.n.038_bib30","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The implications of anemia in multiple myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2006.n.038_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib33","first-page":"25","article-title":"Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin","volume":"30","author":"Barlogie","year":"1993","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2006.n.038_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/stem.5530110203","article-title":"Recombinant human erythropoietin and the anemia of multiple myeloma","volume":"11","author":"Barlogie","year":"1993","journal-title":"Stem Cells"},{"key":"10.3816\/CLM.2006.n.038_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000203625","article-title":"Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia","volume":"98","author":"Mittelman","year":"1997","journal-title":"Acta Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib36","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial","volume":"155","author":"Garton","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.3816\/CLM.2006.n.038_bib37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.6004\/jnccn.2005.0046","article-title":"Cancer-and treatment-related anemia","volume":"3","author":"Rodgers","year":"2005","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3816\/CLM.2006.n.038_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.3816\/CLM.2006.n.038_bib39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0277-5379(91)90248-C","article-title":"Overall vs. tumor-related survival in multiple myeloma. German Myeloma Treatment Group","volume":"27","author":"Peest","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2006.n.038_bib40","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"10.3816\/CLM.2006.n.038_bib41","first-page":"1022","article-title":"Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristineadriamycin-dexamethasone schedules","volume":"88","author":"Cesana","year":"2003","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.n.038_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00001813-199606000-00003","article-title":"Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia","volume":"7","author":"Aviles","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLM.2006.n.038_bib43","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.3816\/CLM.2006.n.038_bib44","first-page":"256","article-title":"Increased incidence of Herpes Zoster Varicella (HZV) reactivation in multiple myleoma (MM) patients (pts) treated with bortezomib: an analysis from the APEX study","volume":"90","author":"Chanan-Khan","year":"2005","journal-title":"Hematologica"},{"key":"10.3816\/CLM.2006.n.038_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib46","doi-asserted-by":"crossref","first-page":"943a","DOI":"10.1182\/blood.V104.11.3463.3463","article-title":"VAD-t (vincristine, Adriamycin, dexamethasone and low-dose thalidomide) is an effective Initials therapy with high response rates for patients with treatment na\u00efve multiple myeloma (MM)","volume":"104","author":"Chanan-Khan","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib48","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdh026","article-title":"Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD Doxil): a phase II multicenter study","volume":"15","author":"Zervas","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib50","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"key":"10.3816\/CLM.2006.n.038_bib51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0404.2003.00203.x","article-title":"Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features","volume":"109","author":"Isoardo","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.3816\/CLM.2006.n.038_bib52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1600-0609.2004.00238.x","article-title":"Common and rare side-effects of lowdose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy","volume":"72","author":"Offidani","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/10428190400015675","article-title":"Arterial thrombosis in four patients treated with thalidomide","volume":"46","author":"Scarpace","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.n.038_bib54","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"Osman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0609.2004.00349.x","article-title":"Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma","volume":"74","author":"Schutt","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib56","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib57","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1538-7836.2003.00084.x","article-title":"Thalidomide and thrombosis in multiple myeloma","volume":"1","author":"Barbui","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.3816\/CLM.2006.n.038_bib59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0002-9343(02)01300-1","article-title":"Thalidomide-associated deep vein thrombosis and pulmonary embolism","volume":"113","author":"Bennett","year":"2002","journal-title":"Am J Med"},{"key":"10.3816\/CLM.2006.n.038_bib60","first-page":"1108","article-title":"Thalidomide and thrombosis in patients with multiple myeloma","volume":"86","author":"Camba","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.n.038_bib61","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib62","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2006.n.038_bib63","first-page":"143","article-title":"Prospective evaluation of low-dose coumadin for prophylaxis of venous thromboembolism in multiple myeloma patients treated with thalidomide-based regimens","volume":"90","author":"Chanan-Khan","year":"2005","journal-title":"Hematologica"},{"key":"10.3816\/CLM.2006.n.038_bib64","doi-asserted-by":"crossref","first-page":"658a","DOI":"10.1182\/blood.V104.11.2397.2397","article-title":"Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM)","volume":"104","author":"Baz","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib65","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.19.15.1177.30571","article-title":"Thalidomide-induced toxic epidermal necrolysis","volume":"19","author":"Horowitz","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.3816\/CLM.2006.n.038_bib66","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJM200009283431315","article-title":"Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma","volume":"343","author":"Rajkumar","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib67","doi-asserted-by":"crossref","first-page":"309b","DOI":"10.1182\/blood.V104.11.4908.4908","article-title":"Osteonecrosis of the jaw associated with pamidronate therapy","volume":"104","author":"Zarychanski","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib68","doi-asserted-by":"crossref","first-page":"216a","DOI":"10.1182\/blood.V104.11.756.756","article-title":"Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia\u00ae and Zometa\u00ae use","volume":"104","author":"Durie","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib69","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2141.2005.05382.x","article-title":"Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma","volume":"128","author":"Vannucchi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.n.038_bib70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"182","author":"Purcell","year":"2005","journal-title":"Med J Aust"},{"key":"10.3816\/CLM.2006.n.038_bib71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10006-005-0616-6","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"9","author":"Schirmer","year":"2005","journal-title":"Mund Kiefer Gesichtschir"},{"key":"10.3816\/CLM.2006.n.038_bib72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.3816\/CLM.2006.n.038_bib73","doi-asserted-by":"crossref","first-page":"308b","DOI":"10.1182\/blood.V104.11.4905.4905","article-title":"Oral cavity avascular bone necrosis -a newly recognized complication of intravenous (IV) bisphosphonate therapy in cancer patients","volume":"104","author":"Schuster","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib74","doi-asserted-by":"crossref","first-page":"861a","DOI":"10.1182\/blood.V104.11.861.861","volume":"104","author":"Kut","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib75","doi-asserted-by":"crossref","first-page":"313b","DOI":"10.1182\/blood.V104.11.4925.4925","article-title":"Bisphosphonate therapy associated with an increased incidence of mandibular\/maxillary osteomyelitis in multiple myeloma patients","volume":"104","author":"Thakkar","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.n.038_bib76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2006.n.038_bib77","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic acid and renal toxicity: data from French adverse effect reporting database","volume":"39","author":"Munier","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.3816\/CLM.2006.n.038_bib78","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:57Z","timestamp":1588918197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1557919011703018"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.n.038","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}